Piezzo M, Chiodini P, Riemma M, Cocco S, Caputo R, Cianniello D, Di Gioia G, Di Lauro V, Rella FD, Fusco G, Iodice G, Nuzzo F, Pacilio C, Pensabene M, Laurentiis MD (2020) Progression-free survival and overall survival of CDK 4/6 inhibitors plus endocrine therapy in metastatic breast cancer: a systematic review and meta-analysis. Int J Mol Sci 21(17):6400. https://doi.org/10.3390/ijms21176400

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Hart L, Campone M, Petrakova K, Winer EP, Janni W, Conte P, Cameron DA, André F, Arteaga CL, Zarate JP, Chakravartty A, Taran T, Le Gac F, Serra P, O’Shaughnessy J (2022) Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med 386(10):942–950

Article  CAS  PubMed  Google Scholar 

Hanahan D (2022) Hallmarks of cancer: new dimensions. Cancer Discov 12(1):31–46. https://doi.org/10.1158/2159-8290.cd-21-1059

Article  CAS  PubMed  Google Scholar 

Broadfield LA, Pane AA, Talebi A, Swinnen JV, Fendt SM (2021) Lipid metabolism in cancer: new perspectives and emerging mechanisms. Dev Cell 56(10):1363–1393. https://doi.org/10.1016/j.devcel.2021.04.013

Article  CAS  PubMed  Google Scholar 

Vogel FCE, Chaves-Filho AB, Schulze A (2024) Lipids as mediators of cancer progression and metastasis. Nat Cancer 5(1):16–29. https://doi.org/10.1038/s43018-023-00702-z

Article  PubMed  Google Scholar 

Cheng H, Wang M, Su J, Li Y, Long J, Chu J, Wan X, Cao Y, Li Q (2022) Lipid metabolism and cancer. Life 12(6):784. https://doi.org/10.3390/life12060784

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bian X, Liu R, Meng Y, Xing D, Xu D, Lu Z (2021) Lipid metabolism and cancer. J Exp Med. https://doi.org/10.1084/jem.20201606

Article  PubMed  PubMed Central  Google Scholar 

Brown JC, Cespedes Feliciano EM, Caan BJ (2018) The evolution of body composition in oncology—epidemiology, clinical trials, and the future of patient care: facts and numbers. J Cachexia Sarcopenia Muscle 9(7):1200–1208. https://doi.org/10.1002/jcsm.12379

Article  PubMed  Google Scholar 

Tolonen A, Pakarinen T, Sassi A, Kyttä J, Cancino W, Rinta-Kiikka I, Pertuz S, Arponen O (2021) Methodology, clinical applications, and future directions of body composition analysis using computed tomography (CT) images: a review. Eur J Radiol 145:109943. https://doi.org/10.1016/j.ejrad.2021.109943

Article  PubMed  Google Scholar 

Deluche E, Leobon S, Desport JC, Venat-Bouvet L, Usseglio J, Tubiana-Mathieu N (2018) Impact of body composition on outcome in patients with early breast cancer. Support Care Cancer 26(3):861–868. https://doi.org/10.1007/s00520-017-3902-6

Article  PubMed  Google Scholar 

Chen GC, Chen SJ, Zhang R, Hidayat K, Qin JB, Zhang YS, Qin LQ (2016) Central obesity and risks of pre- and postmenopausal breast cancer: a dose-response meta-analysis of prospective studies. Obes Rev 17(11):1167–1177. https://doi.org/10.1111/obr.12443

Article  PubMed  Google Scholar 

Cheng E, Kirley J, Cespedes Feliciano EM, Caan BJ (2022) Adiposity and cancer survival: a systematic review and meta-analysis. Cancer Causes Control 33(10):1219–1246. https://doi.org/10.1007/s10552-022-01613-7

Article  PubMed  PubMed Central  Google Scholar 

Shachar SS, Deal AM, Weinberg M, Nyrop KA, Williams GR, Nishijima TF, Benbow JM, Muss HB (2017) Skeletal muscle measures as predictors of toxicity, hospitalization, and survival in patients with metastatic breast cancer receiving taxane-based chemotherapy. Clin Cancer Res 23(3):658–665. https://doi.org/10.1158/1078-0432.ccr-16-0940

Article  CAS  PubMed  Google Scholar 

Zewenghiel L, Lindman H, Valachis A (2018) Impact of body mass index on the efficacy of endocrine therapy in patients with metastatic breast cancer—a retrospective two-center cohort study. Breast 40:136–140. https://doi.org/10.1016/j.breast.2018.05.005

Article  PubMed  Google Scholar 

Trestini I, Carbognin L, Monteverdi S, Zanelli S, De Toma A, Bonaiuto C, Nortilli R, Fiorio E, Pilotto S, Di Maio M, Gasbarrini A, Scambia G, Tortora G, Bria E (2018) Clinical implication of changes in body composition and weight in patients with early-stage and metastatic breast cancer. Crit Rev Oncol Hematol 129:54–66. https://doi.org/10.1016/j.critrevonc.2018.06.011

Article  PubMed  Google Scholar 

Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, Romero D, Abdelmalek MF, Anstee QM, Arab JP, Arrese M, Bataller R, Beuers U, Boursier J, Bugianesi E, Byrne CD, Castro Narro GE, Chowdhury A, Cortez-Pinto H, Newsome PN (2023) A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 78(6):1966–1986. https://doi.org/10.1097/hep.0000000000000520

Article  PubMed  Google Scholar 

Rinella ME (2015) Nonalcoholic fatty liver disease: a systematic review. JAMA 313(22):2263–2273. https://doi.org/10.1001/jama.2015.5370

Article  CAS  PubMed  Google Scholar 

Younossi ZM (2018) The epidemiology of nonalcoholic steatohepatitis. Clin Liver Dis 11(4):92–94. https://doi.org/10.1002/cld.710

Article  Google Scholar 

Nseir W, Abu-Rahmeh Z, Tsipis A, Mograbi J, Mahamid M (2017) Relationship between non-alcoholic fatty liver disease and breast cancer. Isr Med Assoc J 19(4):242–245

PubMed  Google Scholar 

Lovejoy JC, Champagne CM, de Jonge L, Xie H, Smith SR (2008) Increased visceral fat and decreased energy expenditure during the menopausal transition. Int J Obes (Lond) 32(6):949–958. https://doi.org/10.1038/ijo.2008.25

Article  CAS  PubMed  Google Scholar 

Lee S, Jung Y, Bae Y, Yun SP, Kim S, Jo H, Seo HI (2017) Prevalence and risk factors of nonalcoholic fatty liver disease in breast cancer patients. Tumori 103(2):187–192. https://doi.org/10.5301/tj.5000536

Article  CAS  PubMed  Google Scholar 

Lee YS, Lee HS, Chang SW, Lee CU, Kim JS, Jung YK, Kim JH, Seo YS, Yim HJ, Lee CH, Woo SU, Seo JH, Yeon JE, Um SH, Byun KS (2019) Underlying nonalcoholic fatty liver disease is a significant factor for breast cancer recurrence after curative surgery. Medicine (Baltimore) 98(39):e17277. https://doi.org/10.1097/md.0000000000017277

Article  PubMed  Google Scholar 

Taroeno-Hariadi KW, Putra YR, Choridah L, Widodo I, Hardianti MS, Aryandono T (2021) Fatty liver in hormone receptor-positive breast cancer and its impact on patient’s survival. J Breast Cancer 24(5):417–427. https://doi.org/10.4048/jbc.2021.24.e41

Article  PubMed  PubMed Central  Google Scholar 

Francque SM, Van Der Graaff D, Kwanten WJ (2016) Non-alcoholic fatty liver disease and cardiovascular risk: pathophysiological mechanisms and implications. J Hepatol 65(2):425–443. https://doi.org/10.1016/j.jhep.2016.04.005

Article  CAS  PubMed  Google Scholar 

Afifi AM, Saad AM, Al-Husseini MJ, Elmehrath AO, Northfelt DW, Sonbol MB (2020) Causes of death after breast cancer diagnosis: a US population-based analysis. Cancer 126(7):1559–1567. https://doi.org/10.1002/cncr.32648

Article  PubMed  Google Scholar 

Yan M, Wang J, Xuan Q, Dong T, He J, Zhang Q (2017) The relationship between tamoxifen-associated nonalcoholic fatty liver disease and the prognosis of patients with early-stage breast cancer. Clin Breast Cancer 17(3):195–203. https://doi.org/10.1016/j.clbc.2016.12.004

Article  CAS  PubMed  Google Scholar 

Liu CL, Huang JK, Cheng SP, Chang YC, Lee JJ, Liu TP (2006) Fatty liver and transaminase changes with adjuvant tamoxifen therapy. Anticancer Drugs 17(6):709–713. https://doi.org/10.1097/01.cad.0000215056.47695.92

Article  CAS  PubMed  Google Scholar 

Yang YJ, Kim KM, An JH, Lee DB, Shim JH, Lim YS, Lee HC, Lee YS, Ahn JH, Jung KH, Kim SB (2016) Clinical significance of fatty liver disease induced by tamoxifen and toremifene in breast cancer patients. Breast 28:67–72. https://doi.org/10.1016/j.breast.2016.04.017

Article  CAS  PubMed  Google Scholar 

Saphner T, Triest-Robertson S, Li H, Holzman P (2009) The association of nonalcoholic steatohepatitis and tamoxifen in patients with breast cancer. Cancer 115(14):3189–3195. https://doi.org/1